Prospective Research-based Observational Study of Poteligeo® Experience in the Real World in Adult Patients with Mycosis Fungoides and Sézary Syndrome (PROSPER)

Participants diagnosed with mycosis fungoides or Sézary syndrome to be treated with a medicine called Poteligeo® (mogmulizumab-kpkc) are invited to participate in this study.  Mycosis fungoides and Sézary syndrome are the two most common forms of Cutaneous T cell lymphoma. Poteligeo is an approved medicine to treat mycosis fungoides or Sézary syndrome.
While participants will not directly benefit from participating in this study, the information collected may help to improve upon current scientific and medical knowledge and therefore may benefit others in the future. During an observational study, researchers collect information from a group of people who have a certain disease or are receiving a certain medicine. No experimental treatment or medicine is given to patients as part of an observational study.

Inova Scar Cancer
A Division of Inova Fairfax Hospital
8081 Innovation Park Drive
Fairfax, VA 22031

• Participant aged ≥18 years
• Confirmed diagnosis of MF/SS
• Disease staging at enrollment has been completed
• About to commence primary treatment with Poteligeo® as per reimbursed indication
• Participant is willing and able to complete the symptom diary and PROs
• Additional eligibility in protocol

• Participation in an interventional clinical trial
• Additional ineligibility in protocol

For additional information, please go to:  https://clinicaltrials.gov/study/NCT05455931